Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Clostridium Difficile Infection: early-phase trial registry
1 of 3 indexed Recurrent Clostridium Difficile Infection trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Recurrent Clostridium Difficile Infection: 3 US clinical trials tracked, 1 recruiting.
Recurrent Clostridium Difficile Infection is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Finch Research and Development, running 1 of these trials.
Enrollment posture brief
Registry condition recurrent-clostridium-difficile-infection
OPEN 1 | RECR 33% | LATE 1 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Recurrent Clostridium Difficile Infection lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Clostridium Difficile Infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Clostridium Difficile Infection is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Vedanta Biosciences
NCT06237452
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Finch Research and Development
NCT03497806
Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
Rebiotix
NCT01925417
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Clostridium Difficile Infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Clostridium Difficile Infection trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Clostridium Difficile Infection page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Clostridium Difficile Infection trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Finch Research and Development sponsors the most Recurrent Clostridium Difficile Infection trials on record, review their full trial history before evaluating a specific study. See Finch Research and Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Clostridium Difficile Infection condition card totals 3 registered trials; most-linked intervention CP101; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.